European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisenatide - diabetes mellitus, type 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.,

Canada - English - Health Canada

sanofi-aventis canada inc - lixisenatide; lixisenatide - solution - 0.05mg; 0.1mg - lixisenatide 0.05mg; lixisenatide 0.1mg - incretin mimetics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - lixisenatide - solution for injection - 100microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - lixisenatide - solution for injection - 50microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - not applicable

Canada - English - Health Canada

sanofi-aventis canada inc - lixisenatide - solution - 10mcg - lixisenatide 10mcg - incretin mimetics

Canada - English - Health Canada

sanofi-aventis canada inc - lixisenatide - solution - 20mcg - lixisenatide 20mcg - incretin mimetics

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis groupe - lixisenatide - solution for injection - 10 µg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis groupe - lixisenatide - solution for injection - 20 µg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis groupe - lixisenatide - solution for injection - 20 µg